Literature DB >> 1506390

Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease.

W R Hiatt1, E E Wolfel, J G Regensteiner, E P Brass.   

Abstract

Patients with peripheral arterial disease (PAD) have abnormalities of carnitine metabolism that may contribute to their functional impairment. To test the hypothesis that muscle acylcarnitine generation (intermediates in oxidative metabolism) in patients with PAD provides a marker of the muscle dysfunction, 10 patients with unilateral PAD and 6 age-matched control subjects were studied at rest, and the patients were studied during exercise. At rest, biopsies of the gastrocnemius muscle in the patients' nonsymptomatic leg revealed a normal carnitine pool and lactate content compared with control subjects. In contrast, the patients' diseased leg had higher contents of lactate and long-chain acylcarnitines than controls. The muscle short-chain acylcarnitine content in the patients' diseased leg at rest was inversely correlated with peak exercise performance (r = -0.75, P less than 0.05). With graded treadmill exercise, only patients who exceeded their individual lactate threshold had an increase in muscle short-chain acylcarnitine content in the nonsymptomatic leg, which was identical to the muscle carnitine response in normal subjects. In the patients' diseased leg, muscle short-chain acylcarnitine content increased with exercise from 440 +/- 130 to 900 +/- 200 (SE) nmol/g (P less than 0.05). In contrast to the nonsymptomatic leg, there was no increase in muscle lactate content in the diseased leg with exercise, and the change in muscle carnitine metabolism was correlated with exercise duration (r = 0.82, P less than 0.01) and not with the lactate threshold. We conclude that energy metabolism in ischemic muscle of patients with PAD is characterized by the accumulation of acylcarnitines.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506390     DOI: 10.1152/jappl.1992.73.1.346

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  16 in total

1.  Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease.

Authors:  Jennifer L Robbins; W Schuyler Jones; Brian D Duscha; Jason D Allen; William E Kraus; Judith G Regensteiner; William R Hiatt; Brian H Annex
Journal:  J Appl Physiol (1985)       Date:  2011-04-21

2.  Characterization of the peripheral artery disease symptom experience.

Authors:  Erica N Schorr; Cynthia Peden-McAlpine; Diane Treat-Jacobson; Ruth Lindquist
Journal:  Geriatr Nurs       Date:  2015-04-29       Impact factor: 2.361

3. 

Authors:  C Diehm; H Heidrich; F Spengel; K L Schulte; W Theiss
Journal:  Internist (Berl)       Date:  2000-11       Impact factor: 0.743

4.  Percutaneous intervention in peripheral artery disease improves calf muscle phosphocreatine recovery kinetics: a pilot study.

Authors:  Amy M West; Justin D Anderson; Frederick H Epstein; Craig H Meyer; Klaus D Hagspiel; Stuart S Berr; Nancy L Harthun; Arthur L Weltman; Brian H Annex; Christopher M Kramer
Journal:  Vasc Med       Date:  2012-02       Impact factor: 3.239

Review 5.  The effect of exercise on haemodynamics in intermittent claudication: a systematic review of randomized controlled trials.

Authors:  Belinda J Parmenter; Jacqueline Raymond; Maria A Fiatarone Singh
Journal:  Sports Med       Date:  2010-05-01       Impact factor: 11.136

Review 6.  Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits.

Authors:  Naomi M Hamburg; Gary J Balady
Journal:  Circulation       Date:  2011-01-04       Impact factor: 29.690

7.  A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis.

Authors:  Salvatore Santo Signorelli; Pasquale Fatuzzo; Francesco Rapisarda; Sergio Neri; Margherita Ferrante; Gea Oliveri Conti; Roberto Fallico; Luigi Di Pino; Giuseppe Pennisi; Gabriella Celotta; Anzaldi Massimiliano
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 8.  Propionyl-L-carnitine.

Authors:  L R Wiseman; R N Brogden
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

9.  L-propionyl-carnitine protects tissues from ischaemic injury in an 'in vivo' human ischaemia-reperfusion model.

Authors:  Giuseppe Maria Andreozzi; Romeo Martini; Rosa Maria Cordova; Alessandra D'Eri
Journal:  Clin Drug Investig       Date:  2002-11       Impact factor: 2.859

Review 10.  Intermittent claudication: new targets for drug development.

Authors:  Eric P Brass
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.